Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and BioAtla (NASDAQ:BCAB – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.
Analyst Recommendations
This is a summary of recent recommendations for Neurocrine Biosciences and BioAtla, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Neurocrine Biosciences | 0 | 6 | 16 | 1 | 2.78 |
BioAtla | 0 | 0 | 3 | 0 | 3.00 |
Neurocrine Biosciences presently has a consensus target price of $158.36, indicating a potential upside of 8.74%. BioAtla has a consensus target price of $8.67, indicating a potential upside of 501.85%. Given BioAtla’s stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Neurocrine Biosciences.
Institutional and Insider Ownership
Risk and Volatility
Neurocrine Biosciences has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Profitability
This table compares Neurocrine Biosciences and BioAtla’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Neurocrine Biosciences | 16.00% | 14.86% | 10.54% |
BioAtla | N/A | -140.44% | -88.35% |
Valuation and Earnings
This table compares Neurocrine Biosciences and BioAtla’s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Neurocrine Biosciences | $2.12 billion | 6.91 | $249.70 million | $3.63 | 40.12 |
BioAtla | $250,000.00 | 277.15 | -$123.46 million | ($2.49) | -0.58 |
Neurocrine Biosciences has higher revenue and earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Neurocrine Biosciences beats BioAtla on 10 of the 15 factors compared between the two stocks.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
About BioAtla
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.